Profile data is unavailable for this security.
About the company
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.
- Revenue in USD (TTM)28.45bn
- Net income in USD1.85bn
- Incorporated1900
- Employees99.00k
- LocationAbbott Laboratories100 Abbott Park RdNORTH CHICAGO 60064-3500United StatesUSA
- Phone+1 (847) 937-6100
- Websitehttp://www.abbott.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergan plc | 16.04bn | -4.50bn | 59.56bn | 17.80k | -- | 0.8233 | 20.89 | 3.71 | -13.47 | -6.23 | 48.07 | 213.36 | 0.1343 | 2.42 | 6.19 | 901,118.00 | -3.55 | -3.28 | -3.81 | -3.56 | 86.03 | 79.93 | -26.43 | -26.44 | 0.9362 | -0.1073 | 0.2686 | -- | 9.40 | 21.93 | -457.69 | -- | 45.77 | -- |
| Celgene Corporation | 13.58bn | 4.12bn | 62.23bn | 7.47k | 16.52 | 12.15 | 13.52 | 4.58 | 5.20 | 3.56 | 17.13 | 7.06 | 0.4285 | 0.9244 | 7.53 | 1,818,535.00 | 13.01 | 10.55 | 14.31 | 11.81 | 96.44 | 95.71 | 30.36 | 23.63 | 2.36 | -- | 0.7967 | 0.00 | 15.80 | 18.75 | 110.53 | 23.65 | 11.71 | -- |
| Biogen Inc | 12.59bn | 4.14bn | 74.90bn | 7.30k | 18.17 | 5.34 | 14.96 | 5.95 | 19.54 | 13.99 | 59.47 | 66.45 | 0.5327 | 1.87 | 5.83 | 1,725,247.00 | 18.05 | 18.70 | 20.73 | 21.90 | 86.57 | 87.52 | 33.88 | 31.26 | 2.95 | 18.46 | 0.2971 | 0.00 | 7.21 | 17.34 | 0.2674 | 21.89 | 49.69 | -- |
| Bristol-Myers Squibb Co | 21.04bn | 3.82bn | 92.56bn | 23.70k | 24.39 | 7.24 | 19.87 | 4.40 | 2.32 | 0.552 | 12.81 | 7.83 | 0.6374 | 4.76 | 4.98 | 887,763.70 | 11.63 | 8.47 | 16.11 | 11.67 | 70.39 | 74.09 | 18.25 | 16.42 | 1.39 | -- | 0.3737 | 85.44 | 6.94 | 3.35 | -12.43 | 14.78 | 14.00 | 2.63 |
| Eli Lilly And Co | 23.34bn | 3.04bn | 97.22bn | 40.66k | 31.04 | 6.69 | 20.95 | 4.16 | 2.89 | 1.05 | 22.20 | 13.38 | 0.5695 | 1.46 | 5.48 | 574,172.90 | 7.41 | 7.51 | 10.15 | 10.23 | 72.95 | 75.09 | 13.02 | 13.05 | 1.01 | 88.64 | 0.445 | 77.16 | 7.77 | 0.2359 | -37.54 | -16.00 | 0.6168 | 1.20 |
| Gilead Sciences, Inc. | 24.69bn | 8.96bn | 100.38bn | 10.00k | 11.35 | 4.87 | 9.72 | 4.07 | 6.80 | 2.60 | 18.76 | 15.84 | 0.4012 | 3.74 | 6.32 | 2,469,000.00 | 14.59 | 26.85 | 17.33 | 33.34 | 82.12 | 84.60 | 36.35 | 45.39 | 2.75 | 11.26 | 0.5845 | 12.47 | -14.09 | 21.89 | -25.04 | 31.32 | 8.24 | -- |
| Abbott Laboratories | 28.45bn | 1.85bn | 110.10bn | 99.00k | 59.47 | 3.51 | 22.24 | 3.87 | 1.06 | 0.2695 | 16.24 | 17.91 | 0.4012 | 3.16 | 5.77 | 287,323.20 | 2.61 | 3.68 | 2.94 | 4.54 | 56.61 | 55.35 | 6.51 | 8.47 | 1.24 | 3.64 | 0.4092 | 79.68 | 31.35 | 7.53 | 70.56 | 50.22 | -8.76 | -12.01 |
| Amgen, Inc. | 22.94bn | 8.39bn | 128.32bn | 20.80k | 16.78 | 8.27 | 12.46 | 5.59 | 11.56 | 3.04 | 31.56 | 23.44 | 0.3079 | 1.38 | 6.67 | 1,102,837.00 | 11.27 | 9.39 | 13.11 | 10.71 | 82.49 | 80.96 | 36.59 | 31.04 | 3.60 | 28.72 | 0.6947 | 38.42 | -0.6176 | 5.76 | 4.62 | 13.21 | -0.7365 | 26.15 |
| AbbVie Inc | 29.61bn | 9.96bn | 151.40bn | 29.00k | 15.34 | 42.61 | 13.08 | 5.11 | 6.22 | 3.98 | 18.49 | 2.24 | 0.4387 | 4.53 | 5.63 | 1,021,103.00 | 14.79 | 11.53 | 18.30 | 14.88 | 75.78 | 77.27 | 33.71 | 22.44 | 1.10 | 6.88 | 0.913 | 65.15 | 10.06 | 8.95 | 49.97 | 10.99 | 9.70 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2018 | 131.35m | 7.49% |
| Capital Research & Management Co. (Global Investors)as of 31 Mar 2018 | 113.10m | 6.45% |
| BlackRock Fund Advisorsas of 31 Mar 2018 | 79.12m | 4.51% |
| SSgA Funds Management, Inc.as of 31 Mar 2018 | 68.63m | 3.92% |
| Wellington Management Co. LLPas of 31 Mar 2018 | 43.80m | 2.50% |
| Massachusetts Financial Services Co.as of 31 Mar 2018 | 39.81m | 2.27% |
| Northern Trust Investments, Inc.as of 31 Mar 2018 | 26.06m | 1.49% |
| T. Rowe Price Associates, Inc.as of 31 Mar 2018 | 19.60m | 1.12% |
| Geode Capital Management LLCas of 31 Mar 2018 | 19.21m | 1.10% |
| Norges Bank Investment Managementas of 31 Dec 2017 | 18.69m | 1.07% |
